v3.25.1
Commitments and Contingencies - Additional Information (Detail) - USD ($)
3 Months Ended
Jul. 31, 2024
Jan. 26, 2024
Mar. 31, 2025
Mar. 31, 2024
Mar. 17, 2025
Dec. 31, 2024
Sales revenue     $ 18,325,000 $ 11,104,000    
Intangible assets, net     5,447,000     $ 5,570,000
Contingent liability     3,000,000      
Contingent liability, long-term     0     3,000,000
Regenity Biosciences            
Term of agreement 5 years          
Extension term of agreement 5 years          
Payment upon receipt of 510(k) clearance $ 2,000,000          
Additional payment term on or before January 4, 2026          
Intangible assets, net           5,000,000
Contingent liability, long-term     3,000,000     3,000,000
Regenity Biosciences | Maximum            
Additional payment to guarantee manufacturing capacity $ 3,000,000          
Threatened Litigation            
Litigation liability     0     $ 0
PermeaDerm            
Sales revenue     $ 6,000,000      
Percentage of increase in revenue from sale     20.00%      
PermeaDerm | Minimum            
Percentage of share of revenue increased         50.00%  
PermeaDerm | Maximum            
Percentage of share of revenue increased         60.00%  
Stedical Scientific, Inc. | PermeaDerm            
Term of agreement   5 years        
Extension term of agreement   5 years